OncoMatch/Clinical Trials/NCT06908031
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
Is NCT06908031 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PD-1 monoclonal antibody and mFOLFOX6 regimen for rectal adenocarcinoma.
Treatment: PD-1 monoclonal antibody · mFOLFOX6 regimen · Cetuximab · Bevacizumab — To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospective study, providing high-level evidence-based medical evidence for the use in the treatment of high-risk rectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR proficient
pMMR
Required: MSH2 microsatellite stable
MSS
Disease stage
Required: Stage CT3NX
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
No prior anti-cancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Cannot have received: chemotherapy
No prior anti-cancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Cannot have received: targeted therapy
No prior anti-cancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Cannot have received: immunotherapy
No prior anti-cancer treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Cannot have received: anti-PD-1 therapy
history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy
Cannot have received: anti-PD-L1 therapy
history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy
Cannot have received: anti-PD-L2 therapy
history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy
Cannot have received: anti-CTLA-4 therapy
history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy
Lab requirements
Blood counts
white blood cells (wbc) ≥3.0×10^9/l or absolute neutrophil count (anc) ≥1.5×10^9/l; hemoglobin (hgb) ≥80 g/l; platelets (plt) ≥100×10^9/l
Kidney function
creatinine (creat) <1.5 times the upper limit of the normal range
Liver function
liver transaminases (ast/alt) <3.0 times the upper limit of the normal range; total bilirubin (tbil) <1.5 times the upper limit of the normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify